MIP-NPs were prepared by borate-affinity-controlled directional surface printing, which could bind almost all HER2 glycans, prevent the dimerization of HER2 with other EGFR members, block downstream signaling pathways, and thus inhibit the growth of HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.